InsiderTrades.com logo
Martha J. Demski net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Martha Demski Biography and Net Worth

Director of Chimerix

Ms. Demski has served on the Board of Directors since 2005 and was named Chair in June 2018. Ms. Demski also currently serves as a director of Adamas Pharmaceuticals, Inc., ADMA Biologics, Inc., and Equillium Inc., all of which are public biopharmaceutical companies where she chairs the audit committee and is a member of the compensation committee of all three companies. From 2011 to 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinimoto Althea, Inc., now known as Ajinomoto Bio-Pharma Services, a fully integrated contract development and manufacturing organization. From 2008 to 2010, she served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical. Additionally, Ms. Demski has more than 13 years of banking experience with Bank of America.

Ms. Demski is a National Association of Corporate Directors Board Governance Fellow, and she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum in 2017. Ms. Demski earned her B.A. from Michigan State University and an MBA from The University of Chicago Booth School of Business with concentrations in accounting and finance.

What is Martha J. Demski's net worth?

The estimated net worth of Martha J. Demski is at least $615,349.70 as of May 10th, 2023. Ms. Demski owns 72,055 shares of Chimerix stock worth more than $615,350 as of May 2nd. This net worth estimate does not reflect any other assets that Ms. Demski may own. Learn More about Martha J. Demski's net worth.

How do I contact Martha J. Demski?

The corporate mailing address for Ms. Demski and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at ir@chimerix.com. Learn More on Martha J. Demski's contact information.

Has Martha J. Demski been buying or selling shares of Chimerix?

Martha J. Demski has not been actively trading shares of Chimerix within the last three months. Most recently, on Wednesday, May 10th, Martha J. Demski bought 18,000 shares of Chimerix stock. The stock was acquired at an average cost of $1.11 per share, with a total value of $19,980.00. Following the completion of the transaction, the director now directly owns 72,055 shares of the company's stock, valued at $79,981.05. Learn More on Martha J. Demski's trading history.

Who are Chimerix's active insiders?

Chimerix's insider roster includes Michael Alrutz (Senior Vice President and General Counsel), Michael Andriole (President, CEO, and Director), Martha Demski (Director), David Jakeman (Insider), Michelle LaSpaluto (Chief Financial Officer), Allen Melemed (Chief Medical Officer), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.

Are insiders buying or selling shares of Chimerix?

In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 22,045 shares worth more than $92,241.70. The most recent insider tranaction occured on February, 13th when insider Allen S Melemed sold 3,065 shares worth more than $13,792.50. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.

Information on this page was last updated on 2/13/2025.

Martha J. Demski Insider Trading History at Chimerix

See Full Table

Martha J. Demski Buying and Selling Activity at Chimerix

This chart shows Martha J Demski's buying and selling at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Chimerix Company Overview

Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.54
Low: $8.54
High: $8.54

50 Day Range

MA: $8.07
Low: $4.60
High: $8.55

2 Week Range

Now: $8.54
Low: $0.75
High: $8.55

Volume

N/A

Average Volume

2,309,257 shs

Market Capitalization

$801.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A